Mutations of cytosolic Cu/Zn superoxide dismutase 1 (SOD1) in humans and overexpression of mutant human SOD1 genes in transgenic mice are associated with the motor neuron degenerative condition known as amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Gain-of-function toxicity from the mutant protein expressed in motor neurons, associated with its misfolding and aggregation, leads to dysfunction and cell death, associated with paralyzing disease. Here, using hydrogen–deuterium exchange in intact mice in vivo, we have addressed whether an ALS-associated mutant protein, G85R SOD1–YFP, is subject to the same rate of turnover in spinal cord both early in the course of the disease and later. We find that the mutant protein turns over about 10-fold faster than a similarly expressed wild-type fusion and that there is no significant change in the rate of turnover as animals age and disease progresses.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.
Amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) is a progressive neurodegenerative disease affecting motor neurons.1 About 2% of cases are associated with mutations in the abundant cytosolic free radical scavenging enzyme, Cu/Zn superoxide dismutase 1 (SOD1).2, 3 Studies suggest that these mutations lead to a dominant gain of toxic function associated with misfolding and aggregation,3–6 resembling the behavior of several other proteins associated with neurodegenerative disorders. The ability to model the effects of SOD1 mutations in transgenic mice has enabled the investigation of misfolding and aggregation in vivo during the progression of the disease.7–9
We have focused on the ALS-associated SOD1 mutation, G85R, which results in misfolding of SOD1 to such an extent that this mutant subunit does not reach the native state. In particular, it does not acquire the normal intrasubunit disulfide bond (C57–C146), does not become detectably metallated with Cu(II) or Zn(II), and fails to form the normal active homodimer.10 The abnormal protein has been observed to rapidly turn over in transfected cultured cells.11 In transgenic mice, its steady-state level is less than that of equivalently expressed wild-type human SOD1, consistent with more rapid turnover.10 Nevertheless, transgenic animals bearing G85R human SOD1 or a fusion of G85R with yellow fluorescent protein (YFP) develop ALS.9, 10, 12 In the latter animals, we have observed that disease is associated with progressive development of soluble oligomers, detected by gel filtration of spinal cord extracts, and of insoluble aggregates in motor neurons, observed by fluorescence microscopy. These data raised questions, first, as to whether turnover of the fusion protein in vivo was as rapid as observed in the cultured cell system, and, second, as to whether there might be a progressive decrease in the rate of turnover of the G85R SOD1–YFP fusion protein during the course of disease that could account for the apparent progressive increase in oligomers and aggregates of the mutant protein. Here, we have addressed this possibility by carrying out a hydrogen–deuterium exchange experiment in vivo in both mutant G85R SOD1–YFP and wild-type SOD1–YFP transgenic mice, comparing the rate of turnover of the respective SOD1–YFP proteins in spinal cord at early and later times of life.
Results and Discussion
We first tested whether G85R SOD1–YFP is more rapidly turned over than the wild-type SOD1–YFP fusion in stable doxycycline-regulated NSC-34 (neuroblastoma-derived) transformants that we produced. The mutant protein was indeed turned over at least several-fold more rapidly not only largely via the proteasome but also to some extent by the autophagy pathway (see Supporting Information Figs. 1 and 2).
To monitor turnover of SOD1–YFP fusion proteins in mouse spinal cord, where we had observed earlier that the most significant RNA and protein expression is in motor neurons,9 we first deuterated the mice by supplying 8% D2O in the drinking water for 10 weeks, a time period sufficient to achieve significant, although not necessarily equilibrium, deuteration of many proteins, including SOD1–YFP (Refs.13,14; Fig. 1). The deuterium was then chased by returning the water supply to 100% H2O. An initial washout period of 6 days allowed replacement of D2O with H2O in spinal cord extracellular and intracellular fluid and nonessential amino acid pools.13, 14 Subsequently, we monitored the level of deuteration in SOD1–YFP fusion proteins immunoaffinity-captured from the soluble fraction of spinal cord lysates prepared at various times of chase up to ∼ 3 weeks (Fig. 1). In such an approach, if the soluble fusion protein is very stable, its level of deuteration should change slowly during the chase. In contrast, if the protein is relatively unstable, its deuteration would be predicted to change more rapidly as deuterated molecules are degraded and replaced by newly translated, fully protonated protein during the chase.
For technical reasons, it did not prove possible to directly determine the mass of the intact affinity-captured SOD1–YFP fusion proteins. Therefore, tryptic proteolysis was carried out on the captured proteins followed by HPLC/MS (Fig. 1). The largest tryptic peptide, extending from aa 330–370, was well-separated in HPLC and easily detected by MS and was informative for level of deuteration. For example, Figure 2 compares the isotope envelopes of the 4+ charge state of the fully protonated peptide (top panel) and the deuterated peptide obtained from a wild-type animal after 10 weeks of exposure to 8% D2O (lower panel). These profiles, along with those of the 3+ and 5+ charge states, could be reduced to uncharged peptide masses (see inset panels), giving a centroided mass difference of ∼ 5 Da (see Fig. 2 legend for more details).
Wild-type SOD1–YFP and G85R SOD1–YFP animals were sacrificed at various times after commencement of washout, beginning at 4 months of age (D2O having been commenced at 1.5 months), and the masses of this peptide were measured. The data are plotted in Figure 3. Strikingly, even after 18 days, wtSOD1–YFP had lost only ∼ 1 Da, reflecting the extreme stability of the wild-type protein, with a t1/2 ∼ 22 days. By contrast, the G85R SOD1–YFP protein underwent a far more rapid exchange, with deuteration decaying with single exponential kinetics and a half-life of ∼ 2.6 days. By 18 days of washout, it had exchanged to the level of the fully protonated state, indicating that the deuterated protein had turned over and been replaced by newly made, protonated molecules. We then asked whether the mutant protein would be similarly rapidly turned over at a later stage in the course of the disease, at a time when aggregation becomes significant,9 commencing a chase at 7 months of age (D2O started at 4.5 months). Again, the rate of turnover of soluble G85R SOD1–YFP was rapid. [Note that this experiment does not assess turnover of any insoluble, aggregated material because it is not recovered by the immunoaffinity capture step.] We thus conclude that the rate of turnover of the mutant protein is not affected with progression of disease.
In summary, the behavior in vivo of the G85R SOD1–YFP protein responsible for ALS in these transgenic animals resembles that observed in culture, namely, there is rapid turnover of the mutant protein. Importantly, such rapid turnover persists until relatively late in the course of the disease. [Similar experiments in a limited number of animals at 9 months of age, the average life-span of this strain, showed the same rapid turnover (not shown).] Despite such rapid turnover, however, a fraction of the protein accretes into other forms, for example, soluble oligomers and insoluble aggregates, and either of these species or others not so far detected (e.g., misfolded monomers) might be responsible for progressive neuronal damage. Thus, at least before the very terminal stage of disease (the last 3–4 days, where we observe wholesale aggregation throughout the spinal cord including sciatic axons), it appears that a reduction in the rate of proteasomal or autophagosomal turnover is not responsible for onset and progression of disease. Rather, it seems that the high rate of turnover is simply not sufficient to prevent the accumulation of toxic species. Whether this is a function of certain conformations being inaccessible to turnover or simply due to a stochastic effect remains to be seen.
The transgenic mouse strains, wild-type SOD1–YFP strain 592 and mutant G85R SOD1–YFP strain 641, have been described.9 All animal experiments were conducted according to protocols approved by the Yale University Institutional Animal Care and Use Committee.
Mice were injected intraperitoneally with a loading dose of 200 μL of 98% D2O, and their water bottles were then filled with 8%D2O/92% H2O. After 10 weeks, a “chase” was performed by switching to 100% H2O in the water bottle. At various times thereafter, animals were euthanized, and spinal cords were harvested. The cords were immediately homogenized in 50 mM Tris (pH 7.4) with protease inhibitor cocktail (Roche), and soluble SOD–YFP was affinity-captured using anti-YFP antibody matrix as previously described,9 with modifications as follows. After loading the matrix and washing it batchwise with PBS, four 0.2 mL washes with 50 mM Tris (pH 7.4), 8 M urea were carried out to remove SOD–YFP-associated proteins. The essentially pure SOD–YFP was then eluted in acid-urea and further processed for LC–MS, as previously described. One-eighth of the sample was loaded onto a 250 μm i.d. × 1.5 cm C18 (5 μm, Phenomenex) column, and the column was washed with buffer A (0.1% formic acid, 5% acetonitrile). This column was then attached to a 75 μm i.d. × 12 cm C18 (3 μm, Phenomenex) column and the combination mounted in-line to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific) with voltage supplied directly to the column to establish nanoelectrospray ionization. Peptides were eluted with a linear gradient to 80% buffer B (0.1% formic acid, 80% acetonitrile) in buffer A. Analysis of peptide masses was performed using XCalibur and ProMass Deconvolution software (Thermo Scientific).
Cell culture studies, monitoring stability of induced SOD1–YFPs
Stable NSC-34 cell lines with Tet-regulated wt SOD1–YFP or G85R SOD1–YFP expression were produced using the Clontech system. For immunoblot analysis, cells were lysed in 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, and protease inhibitor cocktail (Roche completeMini). The proteins were fractionated in 10% SDS-PAGE, transferred to PVDF membrane (Millipore), and probed with mouse monoclonal antibodies against GAPDH (MAB374: Chemicon) or SOD1 (G-11; Santa Cruz Biotechnology), followed by a rabbit antimouse HRP-conjugated secondary antibody (Jackson Immuno Research Labs). Cells were induced with 0.5 μg/mL doxycycline (Dox) for 12 h to express the fusion proteins. In one protocol, they were washed to remove Dox, returned to the growth medium, and harvested at various times thereafter for immunoblot analysis (S.F.1). In the other protocol, they were washed and then incubated in growth medium with 100 μg/mL cycloheximide to arrest further translation in the presence of inhibitors of the proteasome, 2.5 μM MG-132, or of autophagy, 10 mM 3-methyladenine, and the cells incubated for various times before harvest for analysis.
The authors thank Howard Hughes Medical Institute for generous support of this work.